5 recruiting, 2 completed, 2 unknown, 1 active not recruiting. 7 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 4, Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow SCLC,Extensive Stage: new trials by email Literature Review of SCLC,Extensive Stage trials Research Report on SCLC,Extensive Stage
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-10-15 |
| A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression IBI363（PD-1/IL-2a-bias） - SCLC,Extensive Stage | Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 35 | 2025-12-20 | 2025-12-17 |
| Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy Adebrelimab combined with Etoposide Capsules - SCLC,Extensive Stage | Phase 2 | Recruiting | Tang-Du Hospital | 32 | 2025-08-25 | 2025-12-30 |
| A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer Adebrelimab - SCLC,Extensive Stage | Unknown | Henan Cancer Hospital | 288 | 2024-02-25 | 2024-02-20 | |
| WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metastases HA-WBRT plus SBRT - SCLC,Extensive Stage, Brain Metastases | Phase 1 / Phase 2 | Recruiting | Fudan University | 56 | 2024-01-15 | 2024-02-07 |
| Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC Niraparib - SCLC,Extensive Stage, SLFN11-positive | Phase 2 | Recruiting | ETOP IBCSG Partners Foundation | 44 | 2023-12-20 | 2026-05-29 |
| Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) Pembrolizumab/Olaparib - SCLC,Extensive Stage | Phase 2 | Recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 60 | 2023-03-27 | 2025-06-24 |
| Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC RYZ101 Dose Level 1, RYZ101 Dose Level 2, RYZ101 Dose Level 3 - SCLC,Extensive Stage | Phase 1 | Active not recruiting | RayzeBio, Inc. | 21 | 2022-10-10 | 2026-04-13 |
| TRT for ES-SCLC After First Line Treatment With Immune Checkpoint Inhibitors Thoracic radiotherapy - SCLC,Extensive Stage | Phase 2 | Unknown | Zhejiang Cancer Hospital | 42 | 2022-09-01 | 2022-09-16 |
| A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer AK104 IV infusion；Chiauranib oral - SCLC,Extensive Stage | Phase 1 / Phase 2 | Completed | Akeso | 36 | 2022-08-26 | 2025-03-12 |
| Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance PD-(L)1 antibody immunotherapy - SCLC,Extensive Stage | Completed | Peking University Cancer Hospital & Institute | 168 | 2022-03-29 | 2024-12-16 |
Brain Neoplasms (1) · Carcinoma, Small Cell (1) · Lung Neoplasms (1) · Small Cell Lung Carcinoma (1)
Neoplasms (2) · Neoplasms by Site (2) · Brain Diseases (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Lung Diseases (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1)
Etoposide (3) · Carboplatin (2) · atezolizumab (2) · EC regimen (1) · PM 01183 (1) · Radiosurgery (1) · niraparib (1) · olaparib (1) · pembrolizumab (1)
Akeso (1) · ETOP IBCSG Partners Foundation (1) · Fudan University (1) · Henan Cancer Hospital (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1) · Peking University Cancer Hospital & Institute (1) · RayzeBio, Inc. (1) · SystImmune Inc. (1) · Tang-Du Hospital (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Zhejiang Cancer Hospital (1)
China (5) · Italy (3) · Australia (2) · France (2) · Germany (2) · Spain (2) · United States (2) · Bulgaria (1) · Canada (1) · Czechia (1) · Georgia (1) · Greece (1) · Hungary (1) · Poland (1) · Puerto Rico (1)
Angelo Delmonte (1) · Junliang Cai, MD (1) · Markus Joerger, MD-PhD (1) · Minglei Zhuo, Physician (1) · Petrus De Jong, MD (1) · Xiaojing Lai (1) · Ying Cheng, Professor (1)